Navidea Biopharmaceuticals Inc

Type: Company
Name: Navidea Biopharmaceuticals Inc
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

NAVIDEA BIOPHARMACEUTICALS : Updates on 2014 Annual Meeting Results

Navidea Biopharmaceuticals, Inc. , reported the results of voting at its 2014 Annual Meeting of Stockholders (the Annual Meeting) held July 17 .According to a release, approximately 79 percent of outstanding shares were represented at the meeting.At the ... [Published 4 Traders - Jul 30 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 2 reports

Navidea Biopharmaceuticals to Announce Second Quarter 2014 Financial Results on August 6, 2014

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceuticalcompany focused on precision diagnostic radiopharmaceuticals, todayannounced that the Company will report its financial results for thesecond quarter 2014, on Wednesday, August 6, 2014 ... [Published Street Sweeper - Jul 29 2014]
First reported Jul 27 2014 - Updated Jul 27 2014 - 1 reports

Navidea Partners with Essex Woodland's Rheumco to Develop Radiopharmaceuticals [Professional Services Close - Up]

Navidea Biopharmaceuticals has formed a joint enterprise with Essex Woodlands-backed Rheumco to develop and commercialize radiolabeled diagnostics and therapeutics for rheumatologic and arthritic diseases.According to a media release, the joint enterprise, ... [Published Pharmacy Choice - Jul 27 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Navidea Biopharmaceuticals Reports 2014 Annual Meeting Results

Navidea Biopharmaceuticals, Inc., reported the results of voting at its 2014 Annual Meeting of Stockholders (the Annual Meeting) held July 17. According to a release, approximately 79 percent of outstanding shares were represented at the meeting.At the ... [Published Individual.com - Jul 23 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Navidea Teams with Essex Woodland's Rheumco to Develop Radiopharmaceuticals

Navidea Biopharmaceuticals has formed a joint enterprise with Essex Woodlands-backed Rheumco to develop and commercialize radiolabeled diagnostics and therapeutics for rheumatologic and arthritic diseases. According to a media release, the joint enterprise, ... [Published Individual.com - Jul 21 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 2 reports

Navidea Biopharmaceuticals Announces 2014 Annual Meeting Results

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceuticalcompany focused on precision diagnostic radiopharmaceuticals, todayannounced the results of voting at its 2014 Annual Meeting ofStockholders (the Annual Meeting) held July 17, 2014. ... [Published The CW44 Tampa Bay - Jul 17 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Navidea forms joint venture with rheumatology startup to target arthritis drugs

Navidea Biopharmaceuticals Inc. took a first step toward developing radioactive drugs to treat disease instead of just detect it with the formation of a joint venture with an early stage pharmaceutical company focused on arthritis.Dublin-based Navidea ... [Published Business First of Buffalo - Jul 17 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Navidea forms JV to exploit unmet needs in the autoimmune space

16:38 ET | About: Navidea Biopharmaceuticals (NAVB)Navidea Biopharmaceuticals (NAVB) teams up with Rheumco LLC in a joint venture to develop and commercialize radiolabeled diagnostics and therapeutics for rheumatologic and arthritic diseases. The joint ... [Published Seeking Alpha - Jul 16 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 4 reports

Navidea Joins Essex Woodland’s Rheumco to Develop Radiopharmaceuticals for Detection and Treatment of Arthritic Diseases

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that it has formed a joint enterprise with Essex Woodlands-backed Rheumco, LLC, to develop and commercialize radiolabeled diagnostics and therapeutics for ... [Published Investor's Business Daily - Jul 16 2014]
First reported Jul 08 2014 - Updated Jul 09 2014 - 2 reports

Navidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers (Transcript)

Navidea Biopharmaceuticals, Inc. ( NAVB )Related Biotechnology, Pharmaceutical and Healthcare NewsInvestor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers Conference CallJuly 8, 2014, 08:00 AM ETExecutivesStephen Lai - Associate Professor, ... [Published BioPortfolio - Jul 09 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 3 reports

Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8, 2014

DUBLIN, Ohio--(EON: Enhanced Online News)--Navidea will host a webcast of an investor briefing to discuss the role of sentinel lymph node biopsy in head and neck cancers on Tuesday, July 8, 2014 with a guest speaker, Dr. Stephen Lai. ... [Published EON Science - Jul 02 2014]
First reported Jun 13 2014 - Updated Jun 14 2014 - 4 reports

Navidea Biopharma shares fall after negative report on Lymphoseek

(Reuters) - Navidea Biopharmaceuticals Inc's shares fell as much as 17 percent on Friday after a negative report on TheStreet.com despite the company receiving expanded U.S. approval for its imaging agent. The U.S. Food and Drug Administratio... ... [Published Yahoo! Health News - Jun 13 2014]

Quotes

"We chose to combine our proprietary Tin-117m technology with Navidea's Manocept CD206 receptor- targeting technology due to its unique ability to seek out and attach itself to immune cells responsible for detrimental inflammation in arthritic conditions" said Gilbert Gonzales, M D , Founder, Rheumco, and R-NAV Director
Original Article: NEXT ARTICLE More From BioPortfolio on "Navidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers (Transcript)"
...macrophages present in tumor-draining lymphatic tissue," said Frederick Cope, Ph D , Senior vice president and Chief Scientific Officer of Navidea. "Tumor-positive lymph nodes recruit cells called Tumor-Associated Macrophages, or TAM's, which are rich in CD206 receptors. The ability of Lymphoseek to specifically target and accumulate in macrophages demonstrated in this study led to localization of the product in tumor-draining pathology-positive lymph nodes that was 18 times higher than in all disease-negative lymph nodes. In the clinic, this reliable uptake of Lymphoseek into appropriate tissue allows for accurate removal and assessment of lymph nodes at highest risk of harboring occult metastases."

More Content

All (147) | News (45) | Reports (0) | Blogs (98) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Leading Health Care Stock for Small-Cap Stars i... [Published Equities.com - 3 hours ago]
NAVIDEA BIOPHARMACEUTICALS : Updates on 2014 An... [Published 4 Traders - Jul 30 2014]
Navidea Biopharmaceuticals to Announce Second Q... [Published Street Sweeper - Jul 29 2014]
Navidea Biopharmaceuticals to Announce Second Q... [Published Business Wire Health News - Jul 29 2014]
Navidea Partners with Essex Woodland's Rheumco ... [Published Pharmacy Choice - Jul 27 2014]
Navidea Biopharmaceuticals Reports 2014 Annual ... [Published Individual.com - Jul 23 2014]
Tesamorelin decreased visceral, liver fat among... [Published Orthopedics Today - Jul 21 2014]
Navidea Teams with Essex Woodland's Rheumco to ... [Published Individual.com - Jul 21 2014]
Navidea Biopharmaceuticals Announces 2014 Annua... [Published The CW44 Tampa Bay - Jul 17 2014]
Navidea Biopharmaceuticals Announces 2014 Annua... [Published Business Wire Health News - Jul 17 2014]
Navidea forms joint venture with rheumatology s... [Published Business First of Buffalo - Jul 17 2014]
2nd Quarter Executive Turnover Remains Positive... [Published Management Turnover as Change Agent - Jul 17 2014]
Navidea forms JV to exploit unmet needs in the ... [Published Seeking Alpha - Jul 16 2014]
Navidea Joins Essex Woodland’s Rheumco to Devel... [Published Investor's Business Daily - Jul 16 2014]
Navidea Joins Essex Woodland’s Rheumco to Devel... [Published Digital Journal - Jul 16 2014]
Navidea Joins Essex Woodland's Rheumco, Will De... [Published Benzinga.com - Jul 16 2014]
Navidea Joins Essex Woodland’s Rheumco to Devel... [Published Business Wire Health News - Jul 16 2014]
Navidea Biopharmaceuticals' (NAVB) CEO Michael ... [Published BioPortfolio - Jul 09 2014]
Navidea Webcasting Briefing on Sentinel Lymph N... [Published Individual.com - Jul 08 2014]
Thoratec Acquires Irish Implant Systems Maker [Published Yahoo! Finance - Jul 03 2014]
Navidea to Webcast Investor Briefing on Sentine... [Published EON Science - Jul 02 2014]
Navidea to Webcast Investor Briefing on Sentine... [Published Business Wire Science: Science News - Jul 02 2014]
Navidea to Webcast Investor Briefing on Sentine... [Published Business Wire Health News - Jul 02 2014]
ABIOMED Acquires Germany's Medical Device Maker [Published Yahoo! Finance - Jul 02 2014]
Navidea announces encouraging data from Phase I... [Published PredictWallStreet - Jun 27 2014]
Platinum Management Buys More Echo Therapeutics... [Published InsiderMonkey.com - Jun 25 2014]
FDA grants expanded use for Lymphoseek [Published Dermatology Times - Jun 25 2014]
Amyloid PET imaging development continues despi... [Published FierceMedicalImaging - Jun 23 2014]
Navidea Biopharmaceuticals to Present at the 9t... [Published Business Wire Health News - Jun 17 2014]
Navidea's sNDA for Lymphoseek injection gets FD... [Published Pharmaceutical Technology - Jun 17 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Navidea Biopharmaceuticals to Announce Second Q... [Published Business Wire Health News - Jul 29 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea will report its financial results for the second quarter 2014, on Wednesday, August 6, 2014 before the market opens followed by a conference call with the investment community at 8:30 AM EDT. ...
Navidea Biopharmaceuticals Announces 2014 Annua... [Published Business Wire Health News - Jul 17 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals announced the results of voting at its 2014 Annual Meeting of Stockholders (the Annual Meeting) held July 17, 2014. ...
2nd Quarter Executive Turnover Remains Positive... [Published Management Turnover as Change Agent - Jul 17 2014]
Executive turnover continues in a positive direction despite a slowdown in a few of the key categories.  The trend in executive turnover continues to correlate with the continuing positive news related to job growth in the American economy and the declining ...
Navidea Joins Essex Woodland’s Rheumco to Devel... [Published Business Wire Health News - Jul 16 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea formed a joint enterprise with Essex Woodlands-backed Rheumco, LLC, to develop and commercialize radiolabeled diagnostics and therapeutics for rheumatologic and arthritic diseases. ...
Navidea to Webcast Investor Briefing on Sentine... [Published EON Science - Jul 02 2014]
DUBLIN, Ohio--(EON: Enhanced Online News)--Navidea will host a webcast of an investor briefing to discuss the role of sentinel lymph node biopsy in head and neck cancers on Tuesday, July 8, 2014 with a guest speaker, Dr. Stephen Lai. ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Navidea Announces Restructuring of Pipeline Dev... [Published GlobeNewswire: Advertising News - May 15 2014]
Technical Data on Biotech Equities -- Research ... [Published Financial Services - May 14 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.